Gujarat Kidney & Super Speciality Ltd

Gujarat Kidney & Super Speciality Ltd has reached a significant milestone, with its stock price touching an all-time high of Rs.158.75 on 19 Aug 2026. This achievement reflects the company’s robust performance and sustained upward momentum in the hospital sector.

Gujarat Kidney & Super Speciality Ltd has seen its investment rating upgraded from Hold to Buy, reflecting a marked improvement across technical indicators, financial trends, valuation metrics, and overall quality. This upgrade, effective from 18 Aug 2026, is underpinned by robust quarterly results, bullish technical signals, and a favourable long-term growth outlook despite valuation concerns.

Gujarat Kidney & Super Speciality Ltd has witnessed a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underscored by positive signals from key technical indicators such as the MACD, Bollinger Bands, and Dow Theory, alongside a robust price performance that significantly outpaces the Sensex over recent periods.

After a sustained four-day rally delivering nearly 14% returns, Gujarat Kidney & Super Speciality Ltd surged to a fresh 52-week and all-time high of Rs 155 on 18 Jun 2026, marking a significant milestone for this micro-cap hospital stock amid a broadly subdued market backdrop.

Gujarat Kidney & Super Speciality Ltd has reached a significant milestone by touching its all-time high price of Rs.155 on 18 August 2026, marking a notable achievement in the hospital sector and reflecting the company’s robust performance over recent periods.

Surging to an all-time high of Rs 149.75 on 17 Aug 2026, Gujarat Kidney & Super Speciality Ltd has demonstrated robust price momentum, outpacing its hospital sector peers and defying the broader market's modest retreat. This milestone caps a three-day rally that has delivered a 10.82% gain, underscoring the stock's technical resilience amid a challenging Sensex environment.

Gujarat Kidney & Super Speciality Ltd has reached a significant milestone by touching its all-time high price of Rs.149.75 on 17 August 2026, marking a notable achievement in the hospital sector and reflecting the company’s robust performance in recent trading sessions.

Gujarat Kidney & Super Speciality Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 10 August 2026. However, the analysis and financial metrics presented here reflect the company’s current position as of 17 August 2026, providing investors with an up-to-date view of its fundamentals, returns, and market standing.

Gujarat Kidney & Super Speciality Ltd has recently exhibited a shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. This change is supported by a combination of technical indicators including Bollinger Bands, moving averages, and momentum oscillators, signalling a cautiously optimistic outlook for this micro-cap hospital sector stock.

Gujarat Kidney & Super Speciality Ltd, a micro-cap player in the hospital sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. This change is underscored by mixed signals from key technical indicators such as MACD, RSI, and moving averages, reflecting a period of consolidation after recent price movements. Investors and analysts are closely monitoring these developments as the stock navigates a critical phase in its price action.

Gujarat Kidney & Super Speciality Ltd, a micro-cap player in the hospital sector, has seen its investment rating downgraded from Hold to Sell as of 5 August 2026. This change reflects a complex interplay of technical deterioration, valuation concerns, and mixed financial trends despite strong recent profit growth. The company’s Mojo Score now stands at 47.0, with a Mojo Grade of Sell, signalling caution for investors amid evolving market dynamics.

Gujarat Kidney & Super Speciality Ltd, a micro-cap player in the hospital sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a recent 3.29% gain in daily price, key technical indicators such as the MACD, RSI, and moving averages reveal a complex picture that investors must carefully analyse amid the stock’s strong year-to-date returns.

Gujarat Kidney & Super Speciality Ltd, a micro-cap player in the hospital sector, has witnessed a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. This transition is underscored by a complex interplay of technical indicators including MACD, RSI, Bollinger Bands, and moving averages, reflecting a nuanced market sentiment despite the stock’s year-to-date outperformance against the Sensex.

Gujarat Kidney & Super Speciality Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 July 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 01 August 2026, providing investors with the most up-to-date insight into its performance and outlook.

Gujarat Kidney & Super Speciality Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 09 July 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 21 July 2026, providing investors with the most up-to-date view of its fundamentals, returns, and market standing.

Gujarat Kidney & Super Speciality Ltd, a micro-cap player in the hospital sector, has witnessed a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. This change is underscored by a series of technical indicator signals and price action that suggest improving investor sentiment and potential for further gains.

Gujarat Kidney & Super Speciality Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a marked improvement in technical indicators and solid financial performance. The company’s Mojo Score rose to 52.0, signalling a more balanced outlook amid a micro-cap hospital sector environment. This upgrade follows a comprehensive reassessment across quality, valuation, financial trends, and technical parameters, highlighting both opportunities and challenges for investors.